Prescription for Better Access

Mark Hansan and Dr. Scott Howell
  • 5.0 (19)
  • MEDICINA
  • CADA DOS SEMANAS

With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.

  1. 17 JUL

    The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference

    At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation. Conference Overview Sarah Emond – ICER John O’Brien – National Pharmaceutical Council Annette Powers – Bristol Myers Squibb Ray Pressburger – Accenture Stuart Altman – Power, Politics and Universal Health Care PBMs 340B Program Copay Maximizers Net Price Lilly Direct Indolent Disease, PFS Concomitant Drug HIV & AZT Orphan Drugs Calquence vs Imbruvica Value-Based Contracts Outcome-Based Contracts Disruptive PBMs CostPlus Drugs Fair Access 2024 Drug Rebates Drug Carve-Outs Dynamic Pricing Accelerated Approvals ICER Assessment Questions? Email comments@prescriptionforbetteraccess.com. Follow us on X, LinkedIn, YouTube, and Threads.

  2. 21 MAY

    The Domino Effect: 2025 Trends in Specialty Drug Benefits Report

    Specialty drug benefit design isn't just one decision — it triggers a domino effect impacting employer and health plan costs, patient access, care delivery and patient cost-sharing. In this episode, we unpack PSG’s latest research on how employers and health plans are rethinking specialty strategies amid rising pressure: cost management as a top priority, movement toward rebate alternatives, shifting site of care models, and evolving approaches to affordability and utilization management. Our guests break down where the biggest shifts are happening, what’s still missing, and how smarter benefit design can create better outcomes across the healthcare system. PSG (Pharmaceutical Strategies Group) 2025 Trends in Specialty Drug Benefits Report Specialty Drugs Drug Utilization PBM (Pharmacy Benefit Manager) Copay Assistance (Maximizers & Accumulators) Drug Rebates Drug “Carve Outs” Value-Based Agreements Utilization Management Step Therapy Biosimilars Site-of-Care Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    51 min

  3. 17 ABR

    Inside the Cost Curve: An Interview with Brian Reid

    In this episode, we interview Brian Reid, the founder of Reid Strategic and the creator and editor of our favorite industry newsletter, the Cost Curve. Brian shares his journey to create the Cost Curve and how he navigates the onslaught of information to identify the most important issues of the day. We also get his take on what he calls the highest “importance-to-attention” healthcare stories, highlighting critical topics that are undercovered related to their significance. We also get the opportunity to understand his perspectives on the threats to innovation, the risks to patient affordability programs, and what all of us should be doing to be better healthcare consumers. Brian Reid- Reid Strategic Cost Curve Newsletter Martin Shkreli & Daraprim BioPharma Dive: Biotech and Pharma Industry News GLP-1s Net Price– “a drug’s net price equals the actual revenues that a manufacturer earns from a drug after rebates, discounts, and other reductions” Source: Drug Channels  Armamentarium Pharmacy Benefit Managers (PBMs) Mark Cuban Pharmacy Psuedo-Generic Medication CVS Cordavis Quallent Nuvalia Biosimilars Lilly Direct Novo 340B Drug Pricing Program Copay maximizers AFPs Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    45 min

  4. 20 MAR

    Value in Prescription Drugs – What Does It Really Mean?

    In this episode, we explore the complex and often debated concept of value in prescription drugs. They discuss how different stakeholders—payers, manufacturers, providers, regulators, and patients—define value, and how methodologies like health technology assessments (HTA) and cost-effectiveness analyses shape drug pricing and access. With insights from leading experts, the conversation examines the controversies surrounding value-based pricing, including the role of real-world evidence, quality-adjusted life years (QALYs), and innovation incentives. Can we strike a balance between affordability, innovation, and patient access? And what does the future hold for value-based drug pricing in the U.S.? Tune in for a deep dive into one of the most critical issues in healthcare today. Daniel Ollendorf, Chief Scientific Officer and Director of HTA Methods and Engagement Lou Garrison, Professor Emeritus at University of Washington CHOICE Institute for Clinical and Economic Review (ICER) FDA GLP-1 Drugs Medicare Biosimilars Generics Versus Biosimilars PBMs (Pharmacy Benefit Managers) 340B Drug Pricing Program Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    52 min

  5. 20 FEB

    An interview with Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER)

    In this episode, we interview Sarah Emond, MPP, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah joined ICER over 15 years ago as Chief Operating Officer and was appointed to lead the organization following the retirement of Dr. Steven Pearson. Sarah outlines her vision for ICER and the priorities for strengthening the framework and collaboration to achieve their mission of evaluating the comparative effectiveness of new medicines. Sarah also discusses ICER’s efforts to expand patient engagement and the evaluation of payers to ensure fair access to medicine. Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER) Dr. Steven Pearson, Founder, President, Institute for Clinical and Economic Review (ICER) Barriers to Fair Access Report  Gross-to-Net Bubble Pharmacy Benefit Managers (PBMs) Humira biosimilars Institute for Clinical and Economic Review (ICER) 340B Drug Pricing Program Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    44 min

  6. 18/12/2024

    2025 Outlook with Stacie Dusetzina, Ph.D., Vanderbilt University

    In this episode, we sit down with Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center to discuss the critical healthcare and policy trends shaping 2025. From shifts in federal leadership to the evolving impact of the Inflation Reduction Act, our guest provides expert insights on what to expect in drug pricing, health insurance, and patient access in the coming year. We explore how the public and private sectors are addressing affordability challenges and highlight innovative approaches to improve access to essential medications. With a focus on the future, this conversation offers a thoughtful outlook on the policies and market dynamics set to redefine healthcare in 2025. Stacie Dusetzina, Ph.D., Vanderbilt University Vanderbilt University Medical Center A primer on copay accumulators, copay maximizers, and alternative funding programs CMS  FDA IRA Medicare Part D Pharmacy Benefit Managers (PBMs) Medicaid CMMI’s Medicaid group negotiation  COVID-19 Statins PCSK9 inhibitors Imatinib 340B Drug Pricing Program Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    48 min

  7. 04/12/2024

    Cell and Gene Therapy Access Challenges

    In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies.  Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health Eric Faulkner, President, Passage Health Associates ADVI Health Alliance for Regenerative Medicine ARPA-H Bespoke Gene Therapy Consortium Blue Bird Bio Blue Cross Blue Shield Medicare DRG Rates NICE (National Institute for Health and Care Excellence) Novartis Passage Health Associates REMS Program Single Case Agreements Spark Therapeutics Medical terminology referenced in this episode: Alzheimer's Aspheresis CAR T therapy Hemophilia Hepatitus C Luxturna Metachromatic leukodystrophy  Myeloablative Conditioning Sickle Cell Disease SMA treatment Spinraza Vaso Occlusive Crises Zolgensma

    53 min

  8. 22/10/2024

    Global vs. US Drug Pricing and Market Access

    In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves into the distinct approaches taken by government vs. private markets, examining how regulatory environments, pricing controls, and reimbursement processes impact patient access to innovative therapies. We explore the challenges each approach faces, from cost pressures to affordability and access, and how they balance the interests of patients, governments, and pharmaceutical companies. Join us for a deep dive into how the global healthcare landscape is evolving and what lessons can be learned. Nikos Maniadakis, Ph.D., Professor, Health Management & Policy, University of West Attica Kimberly Baldwin, Senior Vice President, Value & Access, Ipsen Biopharmaceuticals Fauzea Hussain, Vice President, Public Policy, McKesson CMS (Centers for Medicare & Medicaid Services) European Medicines Agency Health technology assessments (HTAs) IRA (Inflation Reduction Act) Medicaid Medicare National Institute of Clinical Excellence (NICE) NCCN guidelines P&T committee (Pharmacy and Therapeutics Committee) PAP (Patient Assistance Program) Part B (Medicare) Part D (Medicare) Pharmacy Benefit Managers (PBMs) Quality-Adjusted Life Years Tricare Veterans Administration Medical terminology referenced in this episode: Cell and gene therapies (CGT) Insulin Orphan drugs Questions or comments? Email us at comments@prescriptionforbetteraccess.com.

    54 min
Ver todo (31)

5
de 5
19 calificaciones

Acerca de

With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.

Información

  • Creador
    Mark Hansan and Dr. Scott Howell
  • Años de actividad
    2023 - 2025
  • Episodios
    31
  • Clasificación
    Apto
  • Copyright
    © 2025 Prescription for Better Access Mark Hansan and Dr. Scott Howell
  • Mostrar sitio web
    Prescription for Better Access

También te podría interesar